Scientists test flu virus on volunteers to speed up vaccine development

NCT ID NCT06613737

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed study tested different doses of an influenza A H3N2 virus in 33 healthy adults aged 18 to 55. The goal was to find a dose that safely causes mild flu symptoms, so this virus strain can be used in future trials to test new vaccines or treatments. Participants were monitored for side effects and infection rates over 28 days.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Influenza A H3N2 virus

What this could lead to

If successful, this study will help researchers safely test future flu vaccines and treatments by using a reliable virus strain that causes mild flu in volunteers.

What could go wrong

This is an early exploratory study with only 33 participants. The virus may not cause infection as expected, or side effects could be more than mild. Results may not apply to everyone.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INFLUENZA A H3N2 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

influenza

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • hVIVO Services Ltd, 40 Bank Street

    London, E14 5NR, United Kingdom